肺腫瘍組織外植片培養:精密切片肺腫瘍スライスを作製および培養する手順

Executive Industry Relevance

Precision-cut lung tumor slice explants preserve native 3D tissue architecture and multicellular interactions, offering a physiologically relevant model for early-stage oncology drug response studies. This approach bridges the gap between reductionist cell line screens and in vivo models, enabling mechanistic de-risking of therapeutic hypotheses before costly preclinical investments. By maintaining tumor microenvironment integrity, the method supports target validation and phenotypic screening with improved translational confidence.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses within intact tumor stroma and parenchyma.
• Operational Value: Provides functional readouts of drug effects on proliferation, apoptosis, and pathway modulation in native tissue context.
• Strategic Value: Reduces false positives by de-risking targets lacking efficacy in complex tissue microenvironments.

Screening & Assay Development

• Scientific Value: Generates quantitative, reproducible viability and biomarker readouts from drug-treated slices.
• Operational Value: Standardizes tissue preparation via vibratome sectioning and rotating incubation for consistent oxygen/nutrient exposure.
• Strategic Value: Supports assay miniaturization and multi-well plate compatibility for medium-throughput compound screening.

Translational & Preclinical Research

• Scientific Value: Maintains histopathological and molecular features of murine lung tumors for preclinical continuity.
• Operational Value: Allows longitudinal sampling and fixed/time-point analysis of drug-treated explants.
• Strategic Value: Informs go/no-go decisions by correlating ex vivo drug response with anticipated in vivo efficacy.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation through lead identification, providing a tissue-based functional assay prior to in vivo efficacy studies.

• Discovery Biology: Supports pathway clarification and target engagement assessment in intact tumor tissue.
• Screening: Enables reproducible compound testing with viability and biomarker outputs under controlled incubation.
• Analytics: Delivers quantitative measurements such as slice integrity, metabolic activity, and protein expression changes.
• Translational Research: Preserves disease-relevant stromal interactions critical for predicting clinical translatability.
• Enterprise Reuse: Establishes a reusable platform for lung oncology projects requiring 3D tissue models.

Operational & Enterprise Impact

• Scientific Value: Enhances predictive confidence by modeling drug responses in native multicellular tumor ecosystems.
• Operational Value: Ensures reproducibility through standardized slicing, grid-based culture, and daily medium replenishment.
• Strategic Value: Improves capital efficiency by filtering ineffective compounds before in vivo studies.
• Portfolio Impact: Enables risk-adjusted prioritization based on ex vivo efficacy and mechanistic consistency.

Implementation Considerations

• Requires expertise in vibratome operation and tissue handling to ensure slice quality and viability.
• Dependent on precision instrumentation including vibratome, rotating incubation unit, and sterile titanium grids.
• Necessitates cross-team standardization of slicing parameters, culture conditions, and treatment protocols.
• Involves adaptation considerations for different tumor models, tissue densities, and drug solubility profiles.
• Limited by slice survival duration and the need for immediate processing post-experiment for molecular analysis.

Biopharma FAQs